9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination

Key Takeaways Explain This Topic AI

Diagnostic evaluation of hyponatremia begins with measured serum osmolality to differentiate true hypotonic hyponatremia from pseudohyponatremia and hypertonic translocational shifts, followed by rigorous volume assessment and urinary solute indices ( U Osm U_{\text{Osm}} U Osm ​ and U Na U_{\text{Na}} U Na ​ ).

Acute symptomatic hyponatremia presenting with seizures, obtundation, or imminent brainstem herniation is a neurological emergency requiring prompt 3% hypertonic saline ( 100 to 150 mL 100\text{ to }150\text{ mL} 100 to 150 mL IV bolus over 10 minutes, repeatable up to three times) targeting an acute rise of 4 to 6 mEq/L 4\text{ to }6\text{ mEq/L} 4 to 6 mEq/L to abort cerebral edema.

In chronic hyponatremia, aim for 4-8 mEq/L per 24 hours; the 2013 US expert panel sets limits of 10-12 mEq/L in 24 hours (18 in 48 hours) for standard-risk patients and 8 mEq/L in 24 hours for patients at high risk of osmotic demyelination (sodium <= 105 mEq/L, hypokalemia, alcohol use disorder, malnutrition, advanced liver disease).

Inadvertent rapid overcorrection caused by spontaneous aquaresis requires active therapeutic intervention with the desmopressin (DDAVP) clamp and intravenous 5% dextrose in water (D5W) to re-lower serum sodium back into safe target parameters.

Hypernatremia correction must not exceed 10 to 12 mEq/L 10\text{ to }12\text{ mEq/L} 10 to 12 mEq/L per 24 hours (approximately 0.5 mEq/L/h 0.5\text{ mEq/L/h} 0.5 mEq/L/h ) to prevent iatrogenic cerebral edema; free water deficit guides crystalloid replacement, while the desmopressin challenge differentiates central from nephrogenic diabetes insipidus.

Last updated: October 2026

Diagnostic Classification and Tonicity Framework

Dysnatremias are disorders of water homeostasis , not total body sodium content. Serum sodium concentration reflects the ratio of total exchangeable sodium and potassium to total body water (the Edelman equation):

Serum [ Na + ] ≈ Exchangeable Na + + Exchangeable K + Total Body Water \text{Serum } [\text{Na}^+] \approx \frac{\text{Exchangeable } \text{Na}^+ + \text{Exchangeable } \text{K}^+}{\text{Total Body Water}} Serum [ Na + ] ≈ Total Body Water Exchangeable Na + + Exchangeable K + ​

Hyponatremia ( [ Na + ] < 135 mEq/L [\text{Na}^+] < 135\text{ mEq/L} [ Na + ] < 135 mEq/L ) represents the most prevalent electrolyte abnormality encountered in the intensive care unit (ICU). A disciplined diagnostic approach requires determining effective serum osmolality (tonicity), followed by clinical extracellular fluid (ECF) volume status and urinary biochemical indices.

Loading diagram...

1. Tonicity Stratification

Hypertonic Hyponatremia ( S Osm > 295 mOsm/kg S_{\text{Osm}} > 295\text{ mOsm/kg} S Osm ​ > 295 mOsm/kg ) : Occurs when impermeant, non-sodium solutes accumulate in the extracellular compartment, generating an osmotic gradient that shifts water out of intracellular space into the vascular bed, diluting serum sodium. The primary etiology is profound hyperglycemia (diabetic ketoacidosis or hyperosmolar hyperglycemic state), as well as intravenous mannitol, sorbitol, or maltose infusions (used in IV immunoglobulin formulations).

Katz Correction Formula : For every 100 mg/dL 100\text{ mg/dL} 100 mg/dL rise in blood glucose above 100 mg/dL 100\text{ mg/dL} 100 mg/dL , measured serum sodium decreases by approximately 1.6 mEq/L 1.6\text{ mEq/L} 1.6 mEq/L : Corrected [ Na + ] = Measured [ Na + ] + 0.016 × ( Glucose − 100 ) \text{Corrected } [\text{Na}^+] = \text{Measured } [\text{Na}^+] + 0.016 \times (\text{Glucose} - 100) Corrected [ Na + ] = Measured [ Na + ] + 0.016 × ( Glucose − 100 )

Hillier Correction Formula : In marked hyperglycemia ( > 400 mg/dL > 400\text{ mg/dL} > 400 mg/dL ), a correction factor of 2.4 mEq/L 2.4\text{ mEq/L} 2.4 mEq/L per 100 mg/dL 100\text{ mg/dL} 100 mg/dL glucose rise provides superior physiologic precision: Corrected [ Na + ] = Measured [ Na + ] + 0.024 × ( Glucose − 100 ) \text{Corrected } [\text{Na}^+] = \text{Measured } [\text{Na}^+] + 0.024 \times (\text{Glucose} - 100) Corrected [ Na + ] = Measured [ Na + ] + 0.024 × ( Glucose − 100 )

Isotonic Pseudohyponatremia ( S Osm = 275 to 295 mOsm/kg S_{\text{Osm}} = 275\text{ to }295\text{ mOsm/kg} S Osm ​ = 275 to 295 mOsm/kg ) : An artifact of laboratory measurement occurring with indirect potentiometry (flame photometry or indirect ion-selective electrodes [ISE]). In normal serum, plasma water comprises 93% of total volume, with solids (lipids and proteins) accounting for the remaining 7%. Extreme hypertriglyceridemia (chylomicronemia > 1500 mg/dL > 1500\text{ mg/dL} > 1500 mg/dL ) or extreme paraproteinemia (multiple myeloma, Waldenström macroglobulinemia, high-dose IVIG) expands the solid non-aqueous phase to 15-20%. Because indirect ISE dilutes the sample before measurement assuming a standard 93% aqueous fraction, sodium concentration is falsely reported as low despite normal active sodium concentration in the aqueous phase. Direct ISE (such as on point-of-care arterial blood gas analyzers) measures undiluted plasma water and is immune to pseudohyponatremia.

Hypotonic Hyponatremia ( S Osm < 275 mOsm/kg S_{\text{Osm}} < 275\text{ mOsm/kg} S Osm ​ < 275 mOsm/kg ) : True hyponatremia characterized by relative excess of free water over sodium.

Hypotonic Hyponatremia: Volume Classification and Diagnostic Indices

Once true hypotonic hyponatremia is confirmed, physical examination of extracellular fluid volume coupled with urine osmolality ( U Osm U_{\text{Osm}} U Osm ​ ) and spot urine sodium ( U Na U_{\text{Na}} U Na ​ ) establishes the underlying etiology:

Volume Status Clinical Features Urine Osmolality ( U Osm U_{\text{Osm}} U Osm ​ ) Urine Sodium ( U Na U_{\text{Na}} U Na ​ ) Primary ICU Etiologies

Hypovolemic Orthostasis, tachycardia, dry mucous membranes, collapsed IVC, poor skin turgor > 300 mOsm/kg > 300\text{ mOsm/kg} > 300 mOsm/kg (ADH stimulated by baroreceptors) < 20 − 30 mEq/L < 20-30\text{ mEq/L} < 20 − 30 mEq/L (avid renal retention) Extrarenal losses: severe vomiting, diarrhea, burns, pancreatitis, capillary leak

Hypovolemic Volume depleted as above, but with inappropriate natriuresis > 300 mOsm/kg > 300\text{ mOsm/kg} > 300 mOsm/kg > 30 − 40 mEq/L > 30-40\text{ mEq/L} > 30 − 40 mEq/L (renal salt wasting) Diuretic therapy (thiazides > loops), Cerebral Salt Wasting (CSW), mineralocorticoid deficiency

Euvolemic Normal turgor, no peripheral edema, flat JVP, normal collapsible IVC < 100 mOsm/kg < 100\text{ mOsm/kg} < 100 mOsm/kg (intact ADH suppression) Variable ( < 20 − 30 mEq/L < 20-30\text{ mEq/L} < 20 − 30 mEq/L ) Psychogenic polydipsia, beer potomania, "tea and toast" low-solute malnutrition

Euvolemic Normal volume, no edema, normal blood pressure > 100 − 300 mOsm/kg > 100-300\text{ mOsm/kg} > 100 − 300 mOsm/kg (inappropriate ADH) > 30 − 40 mEq/L > 30-40\text{ mEq/L} > 30 − 40 mEq/L (euvolemic natriuresis) SIADH, severe secondary adrenal insufficiency, profound hypothyroidism

Hypervolemic Peripheral edema, ascites, elevated JVP, pulmonary rales, dilated IVC > 300 mOsm/kg > 300\text{ mOsm/kg} > 300 mOsm/kg (non-osmotic ADH release) < 20 mEq/L < 20\text{ mEq/L} < 20 mEq/L (avid renal reabsorption from low ECAV) Congestive heart failure, decompensated hepatic cirrhosis, nephrotic syndrome

Hypervolemic Fluid overloaded, oliguric or anuric < 300 mOsm/kg < 300\text{ mOsm/kg} < 300 mOsm/kg (isosthenuric) > 40 mEq/L > 40\text{ mEq/L} > 40 mEq/L (loss of tubular transport) Acute tubular necrosis (ATN), end-stage renal disease (ESRD)

SIADH Diagnostic Criteria (Bartter-Schwartz Criteria)

The Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) requires:

Hypotonic hyponatremia ( S Osm < 275 mOsm/kg S_{\text{Osm}} < 275\text{ mOsm/kg} S Osm ​ < 275 mOsm/kg );

Inappropriate urinary concentration ( U Osm > 100 mOsm/kg U_{\text{Osm}} > 100\text{ mOsm/kg} U Osm ​ > 100 mOsm/kg , frequently > 300 − 500 mOsm/kg > 300-500\text{ mOsm/kg} > 300 − 500 mOsm/kg );

Inappropriate natriuresis ( U Na > 30 − 40 mEq/L U_{\text{Na}} > 30-40\text{ mEq/L} U Na ​ > 30 − 40 mEq/L ) in the setting of standard dietary sodium and fluid intake;

• Strict clinical euvolemia (absence of peripheral edema, ascites, or orthostatic hypovolemia);
• Normal thyroid and adrenal function (euthyroid, eucortisolemic);

Absence of recent diuretic exposure.

SIADH vs. Cerebral Salt Wasting (CSW)

In neurosurgical and neurocritical care patients (e.g., subarachnoid hemorrhage, severe traumatic brain injury, intracranial neoplasms), distinguishing SIADH from CSW is critical because their treatments are diametrically opposed:

• Diagnostic Parameter SIADH Cerebral Salt Wasting (CSW)
• Extracellular Volume Clinically euvolemic (or mildly expanded) Clinically hypovolemic (negative fluid balance)

Serum Uric Acid / FEurate Low uric acid with high FEurate ( > 10 > 10 > 10 - 12 % 12\% 12% ); FEurate normalizes once hyponatremia is corrected Low uric acid with high FEurate that stays elevated after sodium correction

BUN / Creatinine Normal to low ( < 10 : 1 < 10:1 < 10 : 1 ) Elevated ( > 20 : 1 > 20:1 > 20 : 1 , hemoconcentration)

CVP / IVC Collapsibility Normal to elevated ( 6 to 10 mmHg 6\text{ to }10\text{ mmHg} 6 to 10 mmHg ) Depressed ( < 4 mmHg < 4\text{ mmHg} < 4 mmHg , collapsibility > 50 % > 50\% > 50% )

• Urine Volume Oliguric to normal Markedly polyuric ( > 3 L/day > 3\text{ L/day} > 3 L/day )
• Primary Pathology Excessive ADH / V2 receptor activation Brain natriuretic peptide (BNP) / sympathetic loss

Definitive Treatment Fluid restriction , vaptans, urea, salt tablets Volume and sodium repletion ( 0.9 % 0.9\% 0.9% or 3 % 3\% 3% saline), fludrocortisone

Caution

Restricting fluids in a neurocritical patient with Cerebral Salt Wasting will precipitate severe hypovolemic shock, cerebral vasospasm, and secondary ischemic stroke. Volume expansion with isotonic or hypertonic saline is essential in CSW.

Acute Symptomatic Hyponatremia: Neurocritical Emergency Protocol

Acute hyponatremia develops over < 48 hours < 48\text{ hours} < 48 hours , preventing the brain from extruding intracellular organic osmolytes. The osmotic gradient drives water into glial cells and neurons, producing acute cerebral edema , elevated intracranial pressure (ICP), tentorial herniation, respiratory arrest, status epilepticus, and death.

Loading diagram...

Hypertonic Saline Resuscitation Protocol

Immediate Bolus Therapy : For severe neurological manifestations (coma, generalized seizures, stupor, respiratory depression), administer 100 to 150 mL 100\text{ to }150\text{ mL} 100 to 150 mL of 3 % 3\% 3% hypertonic saline IV over 10 minutes 10\text{ minutes} 10 minutes (or 2 mL/kg 2\text{ mL/kg} 2 mL/kg in non-standard weights).

Repeat Dosing : If neurological symptoms persist, repeat the 100 to 150 mL 100\text{ to }150\text{ mL} 100 to 150 mL bolus every 10 to 20 minutes, up to a maximum of three total boluses .

Therapeutic Target : The immediate objective is NOT normalization of serum sodium. An acute elevation of 4 to 6 mEq/L 4\text{ to }6\text{ mEq/L} 4 to 6 mEq/L reduces brain volume by approximately 5%, which is sufficient to reduce ICP, reverse brainstem displacement, and abort status epilepticus.

Discontinuation : Once symptoms resolve or serum sodium increases by 4 to 6 mEq/L 4\text{ to }6\text{ mEq/L} 4 to 6 mEq/L , active hypertonic saline infusions must cease immediately.

Osmotic Demyelination Syndrome (ODS) and Correction Boundaries

In chronic hyponatremia ( > 48 hours > 48\text{ hours} > 48 hours duration), brain cells undergo osmotic adaptation. During the initial 24 to 48 hours, astrocytes extrude inorganic ions ( Na + , K + , Cl − \text{Na}^+, \text{K}^+, \text{Cl}^- Na + , K + , Cl − ) followed by organic osmolytes (myo-inositol, glutamate, taurine, betaine, glutamine) to restore baseline cell volume. While this protects against cerebral edema, it leaves astrocytes vulnerable to dehydration if extracellular tonicity is corrected rapidly.

Pathophysiology and Clinical Presentation of ODS

When chronic hypotonic serum is corrected too rapidly, extracellular tonicity outpaces the slow re-synthesis and re-accumulation of organic osmolytes (which requires several days). Astrocytes dehydrate, undergo apoptotic lysis, disrupt the blood-brain barrier, and trigger non-inflammatory demyelination. The high metabolic activity and crisscrossing white-matter architecture of the pons make it especially vulnerable (Central Pontine Myelinolysis), though extrapontine structures (basal ganglia, thalamus, internal capsules) may also be affected.

Biphasic Course : The patient initially improves as acute encephalopathy clears, followed 2 to 6 days later by progressive, catastrophic neurological decline.

Clinical Manifestations : Spastic quadriparesis, pseudobulbar palsy (dysphagia, dysarthria), mutism, ataxia, and classical "locked-in syndrome" (preserved vertical eye movements and consciousness with complete paralysis of all voluntary motor function). ODS is largely irreversible and carries devastating morbidity.

Absolute Correction Limits

Goal for All Chronic Hyponatremia : A minimum correction of 4 to 8 mEq/L 4\text{ to }8\text{ mEq/L} 4 to 8 mEq/L per 24 hours (4-6 mEq/L is often enough to relieve symptoms).

Standard-Risk Patients : The 2013 US expert panel limit is 10 to 12 mEq/L 10\text{ to }12\text{ mEq/L} 10 to 12 mEq/L in any 24-hour period and 18 mEq/L 18\text{ mEq/L} 18 mEq/L in 48 hours ; the 2014 European guideline uses a limit of 10 mEq/L in the first 24 hours and 8 mEq/L in each subsequent 24 hours. Many ICUs simply treat 8 mEq/L per day as the working ceiling.

High-Risk Patients : Serum sodium ≤ 105 mEq/L \le 105\text{ mEq/L} ≤ 105 mEq/L , hypokalemia, alcohol use disorder, malnutrition, or advanced liver disease (including the peri-liver-transplant period). In these patients:

Target correction rate: 4 to 6 mEq/L 4\text{ to }6\text{ mEq/L} 4 to 6 mEq/L per 24 hours ;

Limit: 8 mEq/L 8\text{ mEq/L} 8 mEq/L in any 24-hour period .

Warning

The most common trigger for unexpected overcorrection is the spontaneous onset of aquaresis (free water diuresis). This occurs when the stimulus for ADH release abruptly ceases—such as volume repletion in hypovolemia, cortisol replacement in adrenal insufficiency, or cessation of a thiazide or SSRI. In this setting, the collecting duct becomes impermeable to water, producing massive dilute polyuria ( U Osm < 100 mOsm/kg U_{\text{Osm}} < 100\text{ mOsm/kg} U Osm ​ < 100 mOsm/kg , urine output > 400 mL/h > 400\text{ mL/h} > 400 mL/h ) that rapidly elevates serum sodium.

Management of Overcorrection: The Desmopressin (DDAVP) Clamp

When serum sodium correction exceeds the limit (or threatens to exceed it, especially in high-risk patients), therapeutic re-lowering should be started promptly to reduce the risk of osmotic demyelination:

Rescue Re-lowering Protocol :

Discontinue all hypertonic fluids, isotonic crystalloids, and salt supplements;

Administer intravenous 5 % 5\% 5% dextrose in water (D5W) at 3 to 5 mL/kg/h 3\text{ to }5\text{ mL/kg/h} 3 to 5 mL/kg/h ;

Administer Desmopressin (DDAVP) 1 to 2 mcg 1\text{ to }2\text{ mcg} 1 to 2 mcg IV or SQ every 6 to 8 hours to activate renal V2 receptors, halt aquaresis, and re-concentrate the urine;

Serial sodium measurements every 2 hours until the serum sodium concentration returns to the target threshold ( 6 to 8 mEq/L 6\text{ to }8\text{ mEq/L} 6 to 8 mEq/L above starting baseline).

Proactive DDAVP Clamp Strategy : In patients with profound chronic hyponatremia ( < 115 mEq/L < 115\text{ mEq/L} < 115 mEq/L ), DDAVP ( 1 − 2 mcg 1-2\text{ mcg} 1 − 2 mcg IV q8h) is administered concurrently with 3 % 3\% 3% hypertonic saline from the start of therapy. This "locks" the renal collecting duct, preventing unexpected spontaneous aquaresis and allowing the clinician to control the rate of sodium elevation using titrated 3 % 3\% 3% saline.

Hypernatremia and Free Water Deficit Calculation

Hypernatremia ( [ Na + ] > 145 mEq/L [\text{Na}^+] > 145\text{ mEq/L} [ Na + ] > 145 mEq/L , severe > 155 − 160 mEq/L > 155-160\text{ mEq/L} > 155 − 160 mEq/L ) always indicates hypertonicity and cellular dehydration. Intact thirst mechanisms normally protect against hypernatremia; therefore, severe hypernatremia in the ICU occurs almost exclusively in patients with impaired thirst, altered sensorium, intubated/sedated states, or restricted access to free water.

Free Water Deficit (FWD) Formula

To restore serum sodium to normal, the clinician must quantify the absolute free water deficit:

FWD = Total Body Water (TBW) × ( Serum [ Na + ] 140 − 1 ) \text{FWD} = \text{Total Body Water (TBW)} \times \left(\frac{\text{Serum }[\text{Na}^+]}{140} - 1\right) FWD = Total Body Water (TBW) × ( 140 Serum [ Na + ] ​ − 1 )

Where Total Body Water (TBW) is calculated based on age and sex:

• Young males: Weight (kg) × 0.6 \text{Weight (kg)} \times 0.6 Weight (kg) × 0.6
• Young females or elderly males: Weight (kg) × 0.5 \text{Weight (kg)} \times 0.5 Weight (kg) × 0.5
• Elderly females: Weight (kg) × 0.45 \text{Weight (kg)} \times 0.45 Weight (kg) × 0.45
• Worked Example

A 70 kg, 72-year-old male with severe dehydration and altered mental status has a serum sodium of 165 mEq/L 165\text{ mEq/L} 165 mEq/L .

Calculate baseline TBW: TBW = 70 kg × 0.5 = 35 L \text{TBW} = 70\text{ kg} \times 0.5 = 35\text{ L} TBW = 70 kg × 0.5 = 35 L

Calculate the Free Water Deficit: FWD = 35 × ( 165 140 − 1 ) = 35 × ( 1.1786 − 1 ) = 35 × 0.1786 ≈ 6.25 Liters \text{FWD} = 35 \times \left(\frac{165}{140} - 1\right) = 35 \times (1.1786 - 1) = 35 \times 0.1786 \approx 6.25\text{ Liters} FWD = 35 × ( 140 165 ​ − 1 ) = 35 × ( 1.1786 − 1 ) = 35 × 0.1786 ≈ 6.25 Liters

Accounting for ongoing insensible losses (sweat, respiration ≈ 30 − 50 mL/h = 800 − 1200 mL/day \approx 30-50\text{ mL/h} = 800-1200\text{ mL/day} ≈ 30 − 50 mL/h = 800 − 1200 mL/day ) and ongoing urinary free water losses, total required water replacement over 48 hours is approximately 8.5 Liters 8.5\text{ Liters} 8.5 Liters .

Correction Rate Limits in Hypernatremia

During chronic hypernatremia ( > 48 hours > 48\text{ hours} > 48 hours ), brain cells accumulate idiogenic osmoles (organic solutes such as taurine, myo-inositol, and amino acids) to preserve cell volume against the hypertonic extracellular environment. If free water is administered too rapidly, water rushes into brain cells along the osmotic gradient, triggering iatrogenic cerebral edema, seizures, permanent neurological injury, and death .

Important

The maximum safe rate of hypernatremia correction is 10 to 12 mEq/L 10\text{ to }12\text{ mEq/L} 10 to 12 mEq/L per 24 hours (approximately 0.5 mEq/L/h 0.5\text{ mEq/L/h} 0.5 mEq/L/h ). Serial serum sodium checks every 2 to 4 hours are mandatory to titrate enteral free water or IV D5W infusions.

Polyuric Syndromes: Central vs. Nephrogenic Diabetes Insipidus

Diabetes insipidus (DI) is characterized by the excretion of large volumes of dilute urine ( > 3 L/24h > 3\text{ L/24h} > 3 L/24h or > 40 − 50 mL/kg/24h > 40-50\text{ mL/kg/24h} > 40 − 50 mL/kg/24h with U Osm < 300 mOsm/kg U_{\text{Osm}} < 300\text{ mOsm/kg} U Osm ​ < 300 mOsm/kg ). When fluid intake does not match urinary losses, severe hypernatremia ensues.

Loading diagram...

Central (Neurogenic) Diabetes Insipidus

Etiologies : Traumatic brain injury, transsphenoidal pituitary surgery, severe hypoxic-ischemic brain injury, intracranial mass lesions, lymphocytic hypophysitis, brain death. In pituitary surgery, a classic triphasic response may occur:

Phase 1 (Days 1-2) : Acute DI from hypothalamic/pituitary shock (polyuria, hypernatremia);

Phase 2 (Days 3-7) : Transient SIADH from uncontrolled leak of preformed ADH from degenerating posterior pituitary axons (oliguria, hyponatremia);

Phase 3 (Day 8+) : Permanent DI once hormone stores are depleted.

Desmopressin Challenge : Exogenous desmopressin ( 1 − 2 mcg 1-2\text{ mcg} 1 − 2 mcg IV or 10 mcg 10\text{ mcg} 10 mcg intranasal) elicits a > 50 % > 50\% > 50% (frequently > 100 − 200 % > 100-200\% > 100 − 200% ) increase in urine osmolality , accompanied by a dramatic reduction in hourly urine volume.

Treatment : Desmopressin titrated to maintain urine output at 1.5 to 2.0 L/day 1.5\text{ to }2.0\text{ L/day} 1.5 to 2.0 L/day , combined with free water replacement via enteral tube or IV D5W.

Nephrogenic Diabetes Insipidus

Etiologies : Chronic lithium therapy (downregulates aquaporin-2 water channels in principal cells), severe hypercalcemia, severe hypokalemia, demeclocycline, amphotericin B, foscarnet, relief of bilateral urinary tract obstruction, sickle cell nephropathy.

Desmopressin Challenge : Exogenous desmopressin produces no significant response (urine osmolality rises by < 50 % < 50\% < 50% , often < 10 % < 10\% < 10% ).

Treatment : Discontinuation of offending drugs; low-sodium, low-protein diet to decrease renal solute load; thiazide diuretics (induce mild volume depletion, promoting proximal tubular sodium and water reabsorption and reducing water delivery to the collecting duct); amiloride (blocks apical epithelial sodium channels [ENaC], specifically blocking lithium entry into principal cells in lithium-induced NDI); indomethacin (inhibits prostaglandin synthesis, enhancing medullary concentrating capacity).